# Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

> **NCT02556203** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 1653 (actual)

## Conditions studied

- Transcatheter Aortic Valve Replacement

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Acetylsalicylic Acid (ASA)
- **DRUG:** Clopidogrel
- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)
- **DRUG:** Vitamin K antagonist (VKA)

## Key facts

- **NCT ID:** NCT02556203
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-16
- **Primary completion:** 2018-11-27
- **Final completion:** 2018-11-27
- **Target enrollment:** 1653 (ACTUAL)
- **Why stopped:** Imbalance in the efficacy and safety endpoints between treatment arms in favor of comparator
- **Last updated:** 2020-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02556203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02556203, "Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02556203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*